Conduit Pharmaceuticals Stock Fundamentals
| CDT Stock | 0.11 0.01 11.00% |
Conduit Pharmaceuticals fundamentals help investors to digest information that contributes to Conduit Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Conduit Stock. The fundamental analysis module provides a way to measure Conduit Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Conduit Pharmaceuticals stock.
Conduit |
Conduit Pharmaceuticals Company Shares Owned By Insiders Analysis
Conduit Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Conduit Pharmaceuticals Shares Owned By Insiders | 49.11 % |
Most of Conduit Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Conduit Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 49.11% of Conduit Pharmaceuticals are shares owned by insiders. This is 223.52% higher than that of the Life Sciences Tools & Services sector and 246.33% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Conduit Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Conduit Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Conduit Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Conduit Pharmaceuticals competition to find correlations between indicators driving Conduit Pharmaceuticals's intrinsic value. More Info.Conduit Pharmaceuticals is rated below average in return on asset category among its peers. It is rated fourth in current valuation category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Conduit Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Conduit Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Conduit Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Conduit Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Conduit Pharmaceuticals by comparing valuation metrics of similar companies.Conduit Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
Conduit Fundamentals
| Return On Asset | -3.22 | ||||
| Current Valuation | 14.98 M | ||||
| Shares Outstanding | 116.8 M | ||||
| Shares Owned By Insiders | 49.11 % | ||||
| Shares Owned By Institutions | 4.05 % | ||||
| Number Of Shares Shorted | 2.36 M | ||||
| EBITDA | (324 K) | ||||
| Net Income | (535 K) | ||||
| Total Debt | 985 K | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (7.72 M) | ||||
| Short Ratio | 0.14 X | ||||
| Earnings Per Share | (0.23) X | ||||
| Beta | 2.12 | ||||
| Market Capitalization | 12.46 M | ||||
| Total Asset | 7.22 M | ||||
| Retained Earnings | (11.3 M) | ||||
| Working Capital | 3.93 M | ||||
| Net Asset | 7.22 M |
About Conduit Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Conduit Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Conduit Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Conduit Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.